Identifying optimal patient subgroups in ovarian cancer for neoadjuvant PARP inhibitor therapy

3/26/2021: Upfront Treatment of Advanced Ovarian Cancer; Ay, Now the Plot ThickensПодробнее

Evaluating future use of PARP inhibitors in neoadjuvant therapy for ovarian cancerПодробнее

The Therapeutic Potential of Novel PARP Inhibitors in the Clinic for Epithelial Ovarian CancerПодробнее

Precision Medicine in Ovarian Cancer With PARP Inhibitor Therapy and Companion DiagnosticsПодробнее

PARP inhibitors as first-line maintenance therapy in ovarian cancerПодробнее

How to determine best first line treatment for ovarian cancer?Подробнее

Dr. O’Malley on the Optimal Use of PARP Inhibitors in Advanced Ovarian CancerПодробнее

Personalizing Advanced Ovarian Cancer Treatment With PARP Inhibitors and Novel ApproachesПодробнее

Biomarker for PARP inhibitor responsiveness in ovarian cancer patientsПодробнее

Assessing the role of PARP inhibitors and immunotherapy in ovarian cancerПодробнее

The Advanced Ovarian Cancer Treatment Palette: Candid Conversations on PARP InhibitorsПодробнее

Updates in PARP inhibition for ovarian cancerПодробнее

Pharmacy Perspectives on PARP Inhibitor Therapy in Ovarian Cancer CareПодробнее

Maintenance Therapy in Ovarian Cancer: PARP InhibitorsПодробнее

Dr. Mirza on Niraparib Efficacy Across Ovarian Cancer SubgroupsПодробнее

Challenges With Targeted Therapies in Ovarian CancerПодробнее

Dr. Konecny on the Value of PARP Inhibitors in Ovarian CancerПодробнее

Is It Time to Change Upfront Chemotherapy for Ovarian Cancer?Подробнее

Novel Therapeutics in Ovarian Cancer: What to WatchПодробнее

PARP Inhibitors in Ovarian Cancer Treatment: Understanding Side EffectsПодробнее